1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,280 | 1,320 | 16:14 | |
| 1,280 | 1,310 | 15:41 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.11. | MaxCyte stellt auf Stephens-Konferenz Neuausrichtung | 1 | Investing.com Deutsch | ||
| 13.11. | MAXCYTE, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 13.11. | MaxCyte reports Q3 results | 1 | Seeking Alpha | ||
| 13.11. | MaxCyte outlines $17M-$19M annualized savings through restructuring while reiterating SPL revenue guidance | 2 | Seeking Alpha | ||
| 12.11. | MaxCyte CFO to step down in first half of 2026 | 2 | Seeking Alpha | ||
| 12.11. | MaxCyte CFO Douglas Swirsky to step down in first half of 2026 | 4 | Investing.com | ||
| 12.11. | MaxCyte, Inc: MaxCyte Announces Planned CFO Transition in 2026 | 99 | GlobeNewswire (Europe) | ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development... ► Artikel lesen | |
| MAXCYTE Aktie jetzt für 0€ handeln | |||||
| 11.11. | Insights into MaxCyte's Upcoming Earnings | 1 | Benzinga.com | ||
| 05.11. | MAXCYTE, INC. - 8-K, Current Report | - | SEC Filings | ||
| 05.11. | MaxCyte reports Q3 results | 1 | Seeking Alpha | ||
| 05.11. | MaxCyte, Inc: MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance | 164 | GlobeNewswire (Europe) | MaxCyte will now host its earnings conference call on November 12, 2025 Management will present at the Stifel Healthcare Conference on November 11, 2025 and Stephens Investment Conference on November... ► Artikel lesen | |
| 08.10. | MaxCyte, Inc: MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025 | 3 | GlobeNewswire (USA) | ||
| 06.10. | MaxCyte, Inc: MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors | 296 | GlobeNewswire (Europe) | ROCKVILLE, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and... ► Artikel lesen | |
| 22.09. | MaxCyte announces 34% workforce reduction to cut costs | 1 | Seeking Alpha | ||
| 22.09. | MAXCYTE, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.09. | MaxCyte, Inc: MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability | 223 | GlobeNewswire (Europe) | ROCKVILLE, Md., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development... ► Artikel lesen | |
| 26.08. | MAXCYTE, INC. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 11.08. | MaxCyte stock rating downgraded to Neutral by BTIG on funding concerns | 11 | Investing.com | ||
| 07.08. | MaxCyte stock downgraded by William Blair to Market Perform on weak guidance | 2 | Investing.com | ||
| 07.08. | MaxCyte revises 2025 core revenue guidance to $29.5M-$32.5M amid customer program consolidation | 1 | Seeking Alpha |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,381 | +0,96 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
| IMMATICS | 8,645 | -1,20 % | Immatics steht 2026 vor dem ersten Durchbruch | ||
| ALDEYRA | 4,288 | +1,32 % | Aldeyra dry eye disease candidate hit by FDA delay amid shifting agency guidance, biotech says | ||
| MEDIFAST | 10,105 | -0,15 % | Can Medifast Overcome GLP-1 Pressure With Its Growth Strategy? | ||
| PHARMING | 1,448 | +3,43 % | Pharming Group N.V.: Pharming Group to participate in Oppenheimer Movers in Rare Disease Summit | Leiden, the Netherlands, December 8, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the Oppenheimer Movers in Rare Disease Summit... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,200 | +2,87 % | Coherus Oncology, Inc.: Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer | - Responsible for Corporate Development, Investor Relations, Government Affairs - REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that... ► Artikel lesen | |
| ORUKA THERAPEUTICS | 27,000 | -0,74 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past three... ► Artikel lesen | |
| INNOVIVA | 17,000 | -0,58 % | FDA Approves Innoviva's NUZOLVENCE, First-in-Class Oral Treatment For Gonorrhea | ||
| ARMATA PHARMACEUTICALS | 4,620 | -11,15 % | Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update | LOS ANGELES, Nov. 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company... ► Artikel lesen | |
| DBV TECHNOLOGIES | 3,460 | -7,86 % | DBV Technologies S.A.: DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN Peanut Patch in Peanut Allergic Children Aged 4-7 Years | Châtillon, France, December 16, 2025
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN Peanut Patch in Peanut Allergic Children Aged 4-7 Years
VITESSE... ► Artikel lesen | |
| BRAINSTORM CELL THERAPEUTICS | 0,673 | -100,00 % | BrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update | NEW YORK, Nov. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 6,250 | -0,16 % | SIGA Technologies - Fundamentals intact amid several moving parts | Q325 was a quieter quarter for SIGA following strong Q2 sales, although this was not unexpected given its contract-driven model and inherent revenue lumpiness. No product sales were recorded, with total... ► Artikel lesen | |
| LIQUIDIA | 29,500 | +0,07 % | Take the Zacks Approach to Beat the Markets: Liquidia, Western Digital & Johnson & Johnson in Focus | ||
| SYNDAX PHARMACEUTICALS | 18,000 | +1,69 % | Syndax Pharmaceuticals Inc - 8-K, Current Report | ||
| MATINAS BIOPHARMA | 0,770 | 0,00 % | Matinas BioPharma ändert Bedingungen für CEO-Halteprämie bei Kontrollwechsel |
Das Unternehmen MAXCYTE INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,280 Euro und damit -0,78 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAXCYTE INC finden Sie auf Wallstreet Online.